Pat Fong William, Li Zi-Jing, Ren Chao, Guan Wen-Long, Zuo Meng-Xuan, Zhang Tian-Qi, Li Bin-Kui, Zheng Yun, Wu Xiao-Jun, Ding Pei-Rong, Chen Gong, Pan Zhi-Zhong, Yuan Yun-Fei, Tan Qiong, Wang Zhi-Qiang, Li Yu-Hong, Wang De-Shen
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Minimally Invasive & Interventional Therapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
HPB (Oxford). 2025 Mar;27(3):289-298. doi: 10.1016/j.hpb.2024.11.008. Epub 2024 Nov 29.
Subsequent lines of therapy for chemotherapy-resistant metastatic colorectal cancer (CRC) have shown limited efficacy. Herein, we retrospectively investigated the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) using oxaliplatin plus 5-FU/FUDR in patients with unresectable colorectal liver metastases (CRLM) who progressed following standard chemotherapy regimens.
From March 2017 to April 2023, CRC patients with unresectable CRLM who progressed following standard chemotherapy and subsequently received HAIC oxaliplatin plus 5-FU/FUDR were evaluated. Objective response rate (ORR), disease control rate (DCR), median depth of tumor response (DpR), no evidence of disease (NED) rate, progression-free survival (PFS), overall survival (OS), and safety were assessed.
A total of 21 patients who progressed after a median of two (range: 1-4) lines of standard systemic chemotherapy were included. The ORR and DCR were 28.6 % and 95.2 %, respectively, with six patients reaching partial response. Additionally, the median DpR was 10.6 %, and seven patients underwent successful conversion surgery. Stratification revealed significantly better PFS in patients with liver-limited metastases compared to those with concurrent hepatic and extrahepatic metastases (P = 0.0003).
HAIC oxaliplatin plus 5-FU/FUDR is a robust regimen for treatment-resistant CRC patients with unresectable CRLM, particularly those with liver-limited disease.
化疗耐药的转移性结直肠癌（CRC）后续治疗线的疗效有限。在此，我们回顾性研究了在接受标准化疗方案后病情进展的不可切除结直肠癌肝转移（CRLM）患者中，使用奥沙利铂联合5-氟尿嘧啶/氟尿苷进行肝动脉灌注化疗（HAIC）的疗效和安全性。
评估2017年3月至2023年4月期间，接受标准化疗后病情进展且随后接受HAIC奥沙利铂联合5-氟尿嘧啶/氟尿苷治疗的不可切除CRLM的CRC患者。评估客观缓解率（ORR）、疾病控制率（DCR）、肿瘤缓解深度中位数（DpR）、无疾病证据（NED）率、无进展生存期（PFS）、总生存期（OS）和安全性。
共纳入21例患者，这些患者在接受中位数为两（范围：1-4）线标准全身化疗后病情进展。ORR和DCR分别为28.6%和95.2%，6例患者达到部分缓解。此外，DpR中位数为10.6%，7例患者成功接受了转化手术。分层分析显示，与同时存在肝内和肝外转移的患者相比肝转移局限的患者PFS显著更好（P = 0.0003）。
HAIC奥沙利铂联合5-氟尿嘧啶/氟尿苷是治疗耐药的不可切除CRLM的CRC患者，特别是肝转移局限患者的有效方案。
